nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—cervical cancer	0.884	1	CbGaD
Pimecrolimus—CYP3A4—Topotecan—cervical cancer	0.017	1	CbGbCtD
Pimecrolimus—MTOR—epithelium—cervical cancer	0.003	0.0641	CbGeAlD
Pimecrolimus—Everolimus—MTOR—cervical cancer	0.00283	0.349	CrCbGaD
Pimecrolimus—MTOR—renal system—cervical cancer	0.00278	0.0594	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—cervical cancer	0.00269	0.0576	CbGeAlD
Pimecrolimus—MTOR—endometrium—cervical cancer	0.00269	0.0574	CbGeAlD
Pimecrolimus—FKBP1A—uterine cervix—cervical cancer	0.00267	0.0571	CbGeAlD
Pimecrolimus—MTOR—mammalian vulva—cervical cancer	0.0026	0.0556	CbGeAlD
Pimecrolimus—FKBP1A—decidua—cervical cancer	0.00255	0.0544	CbGeAlD
Pimecrolimus—FKBP1A—renal system—cervical cancer	0.0025	0.0534	CbGeAlD
Pimecrolimus—MTOR—uterus—cervical cancer	0.00248	0.0529	CbGeAlD
Pimecrolimus—FKBP1A—endometrium—cervical cancer	0.00242	0.0517	CbGeAlD
Pimecrolimus—FKBP1A—mammalian vulva—cervical cancer	0.00234	0.05	CbGeAlD
Pimecrolimus—FKBP1A—uterus—cervical cancer	0.00223	0.0476	CbGeAlD
Pimecrolimus—MTOR—female reproductive system—cervical cancer	0.00223	0.0476	CbGeAlD
Pimecrolimus—MTOR—female gonad—cervical cancer	0.00202	0.0433	CbGeAlD
Pimecrolimus—MTOR—vagina—cervical cancer	0.00201	0.043	CbGeAlD
Pimecrolimus—FKBP1A—female reproductive system—cervical cancer	0.002	0.0428	CbGeAlD
Pimecrolimus—Temsirolimus—MTOR—cervical cancer	0.00191	0.236	CrCbGaD
Pimecrolimus—MTOR—Interferon type I signaling pathways—PIAS3—cervical cancer	0.0019	0.0461	CbGpPWpGaD
Pimecrolimus—FKBP1A—female gonad—cervical cancer	0.00182	0.0389	CbGeAlD
Pimecrolimus—FKBP1A—vagina—cervical cancer	0.00181	0.0387	CbGeAlD
Pimecrolimus—Sirolimus—MTOR—cervical cancer	0.00168	0.208	CrCbGaD
Pimecrolimus—Tacrolimus—MTOR—cervical cancer	0.00168	0.208	CrCbGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—PIAS3—cervical cancer	0.00163	0.0397	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—WNT5A—cervical cancer	0.0015	0.0366	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—YY1—cervical cancer	0.00135	0.0329	CbGpPWpGaD
Pimecrolimus—MTOR—SREBP signalling—YY1—cervical cancer	0.00131	0.0317	CbGpPWpGaD
Pimecrolimus—MTOR—lymph node—cervical cancer	0.0013	0.0278	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—cervical cancer	0.00117	0.025	CbGeAlD
Pimecrolimus—MTOR—Regulation of Telomerase—UBE3A—cervical cancer	0.00102	0.0247	CbGpPWpGaD
Pimecrolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—cervical cancer	0.000901	0.0219	CbGpPWpGaD
Pimecrolimus—CYP3A4—renal system—cervical cancer	0.000817	0.0175	CbGeAlD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—PIAS3—cervical cancer	0.000787	0.0191	CbGpPWpGaD
Pimecrolimus—FKBP1A—TOR Signaling—MTOR—cervical cancer	0.000753	0.0183	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—WNT5A—cervical cancer	0.00066	0.016	CbGpPWpGaD
Pimecrolimus—CYP3A4—female reproductive system—cervical cancer	0.000654	0.014	CbGeAlD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000645	0.0157	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—TERT—cervical cancer	0.000641	0.0156	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—HLA-DPB1—cervical cancer	0.000607	0.0147	CbGpPWpGaD
Pimecrolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CASP3—cervical cancer	0.0005	0.0122	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling—CTNNB1—cervical cancer	0.000497	0.0121	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD8A—cervical cancer	0.000489	0.0119	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—CTNNB1—cervical cancer	0.000482	0.0117	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—cervical cancer	0.000474	0.0115	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFR2 mediated vascular permeability—CTNNB1—cervical cancer	0.000459	0.0112	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—CTNNB1—cervical cancer	0.000434	0.0106	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—STAT3—cervical cancer	0.000421	0.0102	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—TERT—cervical cancer	0.000394	0.00958	CbGpPWpGaD
Pimecrolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000382	0.0093	CbGpPWpGaD
Pimecrolimus—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000368	0.00896	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K Cascade—FGFR3—cervical cancer	0.000362	0.00879	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—cervical cancer	0.000344	0.00836	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CA9—cervical cancer	0.000329	0.008	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—FGFR3—cervical cancer	0.000303	0.00736	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—cervical cancer	0.0003	0.00729	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—STAT3—cervical cancer	0.000295	0.00717	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—FGFR3—cervical cancer	0.000294	0.00715	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—cervical cancer	0.000292	0.00709	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKAP13—cervical cancer	0.000287	0.00698	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—FGFR3—cervical cancer	0.000284	0.0069	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—FGFR3—cervical cancer	0.000284	0.0069	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—STAT3—cervical cancer	0.000284	0.0069	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD4—cervical cancer	0.000281	0.00683	CbGpPWpGaD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—CTNNB1—cervical cancer	0.00028	0.0068	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—FGFR3—cervical cancer	0.00027	0.00656	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CASP3—cervical cancer	0.000268	0.00651	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—STAT3—cervical cancer	0.000264	0.00642	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—FGFR3—cervical cancer	0.000264	0.00641	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—FGFR3—cervical cancer	0.000262	0.00636	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—cervical cancer	0.000256	0.00621	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD4—cervical cancer	0.000254	0.00617	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—CASP3—cervical cancer	0.000243	0.0059	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000241	0.00585	CbGpPWpGaD
Pimecrolimus—MTOR—Interferon type I signaling pathways—STAT3—cervical cancer	0.000236	0.00575	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—FGFR3—cervical cancer	0.000236	0.00574	CbGpPWpGaD
Pimecrolimus—MTOR—CDC42 signaling events—CTNNB1—cervical cancer	0.00022	0.00536	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—STAT3—cervical cancer	0.000217	0.00528	CbGpPWpGaD
Pimecrolimus—MTOR—LKB1 signaling events—TP53—cervical cancer	0.000217	0.00526	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—EGFR—cervical cancer	0.000215	0.00523	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—cervical cancer	0.000215	0.00521	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—EGFR—cervical cancer	0.000204	0.00497	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—STAT3—cervical cancer	0.000204	0.00496	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FGFR3—cervical cancer	0.000202	0.00491	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—STAT3—cervical cancer	0.000201	0.0049	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CTNNB1—cervical cancer	0.000198	0.00482	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—cervical cancer	0.000193	0.00469	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—cervical cancer	0.000191	0.00463	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—FGFR3—cervical cancer	0.00019	0.00462	CbGpPWpGaD
Pimecrolimus—Dysmenorrhoea—Topotecan—cervical cancer	0.000186	0.0746	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000182	0.00443	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—STAT3—cervical cancer	0.000182	0.00442	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—FGFR3—cervical cancer	0.000182	0.00441	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FGFR3—cervical cancer	0.000181	0.00439	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—cervical cancer	0.00018	0.00439	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—FGFR3—cervical cancer	0.00018	0.00437	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FGFR3—cervical cancer	0.000179	0.00435	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—EGFR—cervical cancer	0.000179	0.00435	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—WNT2—cervical cancer	0.000178	0.00433	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—UBE3A—cervical cancer	0.000176	0.00429	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—cervical cancer	0.000176	0.00429	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000176	0.00427	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—cervical cancer	0.000172	0.00417	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—cervical cancer	0.000168	0.00409	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FGFR3—cervical cancer	0.000168	0.00409	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGFR3—cervical cancer	0.000168	0.00409	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FGFR3—cervical cancer	0.000167	0.00405	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—STAT3—cervical cancer	0.000166	0.00404	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	0.000166	0.00404	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—cervical cancer	0.000165	0.00402	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGFR3—cervical cancer	0.000165	0.004	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CASP8—cervical cancer	0.000163	0.00397	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TAAR6—cervical cancer	0.00016	0.00389	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	0.000157	0.00382	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGFR3—cervical cancer	0.000156	0.00379	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—cervical cancer	0.000156	0.00378	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	0.000149	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—cervical cancer	0.000148	0.00361	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—CTNNB1—cervical cancer	0.000148	0.0036	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—cervical cancer	0.000148	0.0036	CbGpPWpGaD
Pimecrolimus—Ear pain—Topotecan—cervical cancer	0.000144	0.0577	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000139	0.00338	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—STAT3—cervical cancer	0.000139	0.00338	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—WNT5A—cervical cancer	0.000135	0.00328	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—EGFR—cervical cancer	0.000133	0.00324	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—EGFR—cervical cancer	0.00013	0.00317	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—EGFR—cervical cancer	0.000129	0.00314	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—CASP3—cervical cancer	0.000128	0.00312	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—cervical cancer	0.000126	0.00307	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—EGFR—cervical cancer	0.000126	0.00307	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—WNT2—cervical cancer	0.000125	0.00303	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—CTNNB1—cervical cancer	0.000124	0.00301	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000124	0.00301	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000119	0.0029	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000117	0.00284	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGFR3—cervical cancer	0.000115	0.00279	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—STAT3—cervical cancer	0.00011	0.00267	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKAP13—cervical cancer	0.00011	0.00266	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—STAT3—cervical cancer	0.000108	0.00262	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—UBE3A—cervical cancer	0.000107	0.0026	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000106	0.00258	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000105	0.00256	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—WNT2—cervical cancer	0.0001	0.00244	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—EGFR—cervical cancer	9.97e-05	0.00242	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—STAT3—cervical cancer	9.87e-05	0.0024	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	9.82e-05	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—cervical cancer	9.54e-05	0.00232	CbGpPWpGaD
Pimecrolimus—Pneumonia—Topotecan—cervical cancer	9.53e-05	0.0381	CcSEcCtD
Pimecrolimus—Infestation NOS—Topotecan—cervical cancer	9.47e-05	0.0379	CcSEcCtD
Pimecrolimus—Infestation—Topotecan—cervical cancer	9.47e-05	0.0379	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—WNT5A—cervical cancer	9.46e-05	0.0023	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—cervical cancer	9.44e-05	0.0023	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—EGFR—cervical cancer	9.39e-05	0.00228	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—STAT3—cervical cancer	9.15e-05	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TAAR6—cervical cancer	8.99e-05	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—EGFR—cervical cancer	8.97e-05	0.00218	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—STAT3—cervical cancer	8.95e-05	0.00217	CbGpPWpGaD
Pimecrolimus—Epistaxis—Topotecan—cervical cancer	8.94e-05	0.0358	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	8.93e-05	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—EGFR—cervical cancer	8.93e-05	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—EGFR—cervical cancer	8.88e-05	0.00216	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—EGFR—cervical cancer	8.84e-05	0.00215	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	8.71e-05	0.00212	CbGpPWpGaD
Pimecrolimus—Rhinitis—Topotecan—cervical cancer	8.53e-05	0.0341	CcSEcCtD
Pimecrolimus—Pharyngitis—Topotecan—cervical cancer	8.44e-05	0.0338	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—EGFR—cervical cancer	8.31e-05	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—EGFR—cervical cancer	8.31e-05	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	8.31e-05	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—EGFR—cervical cancer	8.24e-05	0.002	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DQB1—cervical cancer	8.22e-05	0.002	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—cervical cancer	8.17e-05	0.00199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—EGFR—cervical cancer	8.13e-05	0.00198	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	8.1e-05	0.00197	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—cervical cancer	7.93e-05	0.00193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HES1—cervical cancer	7.77e-05	0.00189	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—EGFR—cervical cancer	7.69e-05	0.00187	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Topotecan—cervical cancer	7.68e-05	0.0308	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—cervical cancer	7.68e-05	0.00187	CbGpPWpGaD
Pimecrolimus—Mediastinal disorder—Topotecan—cervical cancer	7.66e-05	0.0307	CcSEcCtD
Pimecrolimus—MTOR—Disease—WNT5A—cervical cancer	7.6e-05	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—CASP3—cervical cancer	7.42e-05	0.0018	CbGpPWpGaD
Pimecrolimus—Malnutrition—Topotecan—cervical cancer	7.4e-05	0.0296	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	7.36e-05	0.00179	CbGpPWpGaD
Pimecrolimus—Back pain—Topotecan—cervical cancer	7.16e-05	0.0287	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—WNT2—cervical cancer	7.02e-05	0.00171	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—cervical cancer	6.83e-05	0.00166	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TERT—cervical cancer	6.81e-05	0.00166	CbGpPWpGaD
Pimecrolimus—Angioedema—Topotecan—cervical cancer	6.76e-05	0.0271	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—cervical cancer	6.64e-05	0.00162	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH2—cervical cancer	6.64e-05	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGFR3—cervical cancer	6.54e-05	0.00159	CbGpPWpGaD
Pimecrolimus—Cough—Topotecan—cervical cancer	6.46e-05	0.0259	CcSEcCtD
Pimecrolimus—MTOR—Immune System—HLA-DPB1—cervical cancer	6.39e-05	0.00155	CbGpPWpGaD
Pimecrolimus—Arthralgia—Topotecan—cervical cancer	6.3e-05	0.0252	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—FGFR3—cervical cancer	6.28e-05	0.00153	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	6.26e-05	0.0251	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—FGFR3—cervical cancer	6.25e-05	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—cervical cancer	6.23e-05	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKAP13—cervical cancer	6.16e-05	0.0015	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Topotecan—cervical cancer	6.04e-05	0.0242	CcSEcCtD
Pimecrolimus—Infection—Topotecan—cervical cancer	6e-05	0.024	CcSEcCtD
Pimecrolimus—Nervous system disorder—Topotecan—cervical cancer	5.93e-05	0.0237	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—NOTCH1—cervical cancer	5.87e-05	0.00143	CbGpPWpGaD
Pimecrolimus—Skin disorder—Topotecan—cervical cancer	5.87e-05	0.0235	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—cervical cancer	5.66e-05	0.00138	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CASP8—cervical cancer	5.59e-05	0.00136	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Topotecan—cervical cancer	5.51e-05	0.022	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—HES1—cervical cancer	5.44e-05	0.00132	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Topotecan—cervical cancer	5.43e-05	0.0217	CcSEcCtD
Pimecrolimus—Dyspnoea—Topotecan—cervical cancer	5.39e-05	0.0216	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—WNT5A—cervical cancer	5.32e-05	0.00129	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Topotecan—cervical cancer	5.22e-05	0.0209	CcSEcCtD
Pimecrolimus—Pain—Topotecan—cervical cancer	5.17e-05	0.0207	CcSEcCtD
Pimecrolimus—Constipation—Topotecan—cervical cancer	5.17e-05	0.0207	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—cervical cancer	5.07e-05	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DQB1—cervical cancer	4.99e-05	0.00121	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Topotecan—cervical cancer	4.94e-05	0.0198	CcSEcCtD
Pimecrolimus—Urticaria—Topotecan—cervical cancer	4.8e-05	0.0192	CcSEcCtD
Pimecrolimus—Abdominal pain—Topotecan—cervical cancer	4.78e-05	0.0191	CcSEcCtD
Pimecrolimus—Body temperature increased—Topotecan—cervical cancer	4.78e-05	0.0191	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—TERT—cervical cancer	4.77e-05	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—cervical cancer	4.66e-05	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—cervical cancer	4.59e-05	0.00112	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Topotecan—cervical cancer	4.45e-05	0.0178	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—cervical cancer	4.41e-05	0.00107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTOR—cervical cancer	4.4e-05	0.00107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—cervical cancer	4.39e-05	0.00107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR3—cervical cancer	4.38e-05	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HES1—cervical cancer	4.37e-05	0.00106	CbGpPWpGaD
Pimecrolimus—Pruritus—Topotecan—cervical cancer	4.27e-05	0.0171	CcSEcCtD
Pimecrolimus—Diarrhoea—Topotecan—cervical cancer	4.13e-05	0.0165	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH1—cervical cancer	4.11e-05	0.000999	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTNNB1—cervical cancer	4.08e-05	0.000991	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CTNNB1—cervical cancer	3.9e-05	0.000948	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—cervical cancer	3.84e-05	0.000934	CbGpPWpGaD
Pimecrolimus—Vomiting—Topotecan—cervical cancer	3.84e-05	0.0154	CcSEcCtD
Pimecrolimus—MTOR—Disease—TERT—cervical cancer	3.83e-05	0.000931	CbGpPWpGaD
Pimecrolimus—Rash—Topotecan—cervical cancer	3.81e-05	0.0153	CcSEcCtD
Pimecrolimus—MTOR—Immune System—FGFR3—cervical cancer	3.81e-05	0.000926	CbGpPWpGaD
Pimecrolimus—Dermatitis—Topotecan—cervical cancer	3.81e-05	0.0152	CcSEcCtD
Pimecrolimus—Headache—Topotecan—cervical cancer	3.79e-05	0.0152	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH2—cervical cancer	3.73e-05	0.000908	CbGpPWpGaD
Pimecrolimus—Nausea—Topotecan—cervical cancer	3.59e-05	0.0144	CcSEcCtD
Pimecrolimus—MTOR—Disease—FGFR3—cervical cancer	3.52e-05	0.000855	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—cervical cancer	3.4e-05	0.000826	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOTCH1—cervical cancer	3.3e-05	0.000802	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—cervical cancer	3.26e-05	0.000792	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—cervical cancer	3.23e-05	0.000785	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—cervical cancer	3.1e-05	0.000754	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—cervical cancer	3.09e-05	0.000751	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MTOR—cervical cancer	3.08e-05	0.000749	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HES1—cervical cancer	3.06e-05	0.000744	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—cervical cancer	2.83e-05	0.000689	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—cervical cancer	2.73e-05	0.000664	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—cervical cancer	2.68e-05	0.000652	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—cervical cancer	2.67e-05	0.00065	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—cervical cancer	2.47e-05	0.0006	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR3—cervical cancer	2.46e-05	0.000599	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—cervical cancer	2.38e-05	0.000579	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—cervical cancer	2.38e-05	0.000577	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH1—cervical cancer	2.31e-05	0.000562	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—cervical cancer	2.19e-05	0.000533	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—cervical cancer	2.16e-05	0.000526	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA9—cervical cancer	2.1e-05	0.000511	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—cervical cancer	2.07e-05	0.000503	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—cervical cancer	1.91e-05	0.000465	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—cervical cancer	1.88e-05	0.000457	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—cervical cancer	1.82e-05	0.000442	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—cervical cancer	1.74e-05	0.000422	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—cervical cancer	1.59e-05	0.000387	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—cervical cancer	1.54e-05	0.000373	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—cervical cancer	1.34e-05	0.000325	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—cervical cancer	1.22e-05	0.000296	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—cervical cancer	1.02e-05	0.000248	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—cervical cancer	8.53e-06	0.000207	CbGpPWpGaD
